155 related articles for article (PubMed ID: 10782148)
1. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
2. Fas and Fas ligand expression in tumor cells and in vascular smooth-muscle cells of colonic and renal carcinomas.
Peduto Eberl L; Guillou L; Saraga E; Schröter M; French LE; Tschopp J; Juillerat-Jeanneret L
Int J Cancer; 1999 May; 81(5):772-8. PubMed ID: 10328232
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of immune escape in renal cell carcinoma].
Zheng J; Sun X; Chen J; Jiang F; Li W; Xie S
Zhonghua Zhong Liu Za Zhi; 2002 Jan; 24(1):24-6. PubMed ID: 11977630
[TBL] [Abstract][Full Text] [Related]
4. Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma.
Sejima T; Isoyama T; Miyagawa I
Int J Urol; 2003 Sep; 10(9):476-84. PubMed ID: 12941126
[TBL] [Abstract][Full Text] [Related]
5. Absence of Fas (CD95) and FasL (CD95L) immunohistochemical expression suggests Fas/FasL-mediated apoptotic signal is not relevant in cutaneous Kaposi's sarcoma lesions.
Fernández-Figueras MT; Armengol P; Puig L; Molinero JL; Esquius M; Sirera G; Ariza A
J Cutan Pathol; 1999 Oct; 26(9):417-23. PubMed ID: 10563496
[TBL] [Abstract][Full Text] [Related]
6. Fas labeling status does not correlate with apoptosis of renal cell carcinoma in vivo.
Koga F; Arai K; Kamai T; Abe H; Yoshida K
Anticancer Res; 2001; 21(5):3193-7. PubMed ID: 11848472
[TBL] [Abstract][Full Text] [Related]
7. Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli.
Lorz C; Ortiz A; Justo P; González-Cuadrado S; Duque N; Gómez-Guerrero C; Egido J
J Am Soc Nephrol; 2000 Jul; 11(7):1266-1277. PubMed ID: 10864583
[TBL] [Abstract][Full Text] [Related]
8. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger A; Egle A; Marschitz I; Kos M; Böck G; Ludwig H; Geley S; Kofler R; Greil R
Blood; 1997 Jul; 90(1):12-20. PubMed ID: 9207432
[TBL] [Abstract][Full Text] [Related]
9. Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.
O'Connell J; Bennett MW; O'Sullivan GC; O'Callaghan J; Collins JK; Shanahan F
Clin Diagn Lab Immunol; 1999 Jul; 6(4):457-63. PubMed ID: 10391843
[TBL] [Abstract][Full Text] [Related]
10. Fas (Apo-1, CD95) receptor expression in childhood astrocytomas. Is it a marker of the major apoptotic pathway or a signaling receptor for immune escape of neoplastic cells?
Bodey B; Bodey B; Siegel SE; Kaiser HE
In Vivo; 1999; 13(4):357-73. PubMed ID: 10586378
[TBL] [Abstract][Full Text] [Related]
11. Fas-related apoptosis in gastric adenocarcinoma.
Lim SC
Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
[TBL] [Abstract][Full Text] [Related]
12. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
[TBL] [Abstract][Full Text] [Related]
13. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations.
Korkolopoulou P; Goudopoulou A; Voutsinas G; Thomas-Tsagli E; Kapralos P; Patsouris E; Saetta AA
Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.
Yamana K; Bilim V; Hara N; Kasahara T; Itoi T; Maruyama R; Nishiyama T; Takahashi K; Tomita Y
Br J Cancer; 2005 Sep; 93(5):544-51. PubMed ID: 16091761
[TBL] [Abstract][Full Text] [Related]
15. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):101-11. PubMed ID: 14529668
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo.
Lee SH; Jang JJ; Lee JY; Kim SY; Park WS; Kim CS; Kim SH; Yoo NJ
APMIS; 1998 Nov; 106(11):1035-40. PubMed ID: 9890264
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.
Zhu Q; Liu JY; Xu HW; Yang CM; Zhang AZ; Cui Y; Wang HB
World J Gastroenterol; 2005 Oct; 11(39):6125-9. PubMed ID: 16273638
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy].
Sejima T; Miyagawa I
Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of altered Fas (CD95)-system in human breast cancer.
Mottolese M; Buglioni S; Bracalenti C; Cardarelli MA; Ciabocco L; Giannarelli D; Botti C; Natali PG; Concetti A; Venanzi FM
Int J Cancer; 2000 Mar; 89(2):127-32. PubMed ID: 10754489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
